An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.

The study is being conducted to evaluate the efficacy, and safety of SHR-A2009 combined with other anti-tumor therapies for perioperative treatment of resectable non-small cell lung cancer in adults.

Trial Details

NCT ID
NCT07863167
Phase
PHASE2
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • adebrelimab + SHR-A2009
  • paclitaxel or pemetrexed combined with carboplatin +adebrelimab
  • adebrelimab
  • adebeliizumab + SHR-A2009
  • adebeliizumab + platinum-containing double chemotherapy
  • almonertinib combined with SHR-A2009
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ;
  • At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can.
  • The ECOG score was 0 or 1.
  • Pathologically confirmed NSCLC, assessed as resectable or previously resected (R0).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →